X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (194) 194
Publication (19) 19
Patent (8) 8
Book Chapter (3) 3
Book / eBook (2) 2
Newspaper Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (99) 99
male (60) 60
hematology (59) 59
female (56) 56
adult (53) 53
index medicus (52) 52
middle aged (52) 52
aged (47) 47
oncology (43) 43
cancer (26) 26
adolescent (20) 20
chemotherapy (20) 20
lymphoma (19) 19
multiple myeloma (18) 18
aged, 80 and over (17) 17
bortezomib (16) 16
multiple myeloma - drug therapy (16) 16
recurrence (16) 16
lymphomas (15) 15
therapy (15) 15
survival (14) 14
patients (13) 13
retrospective studies (13) 13
treatment outcome (13) 13
abridged index medicus (12) 12
antineoplastic agents - adverse effects (12) 12
antineoplastic agents - therapeutic use (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
care and treatment (11) 11
dexamethasone (11) 11
disease-free survival (11) 11
leukemia (11) 11
prognosis (11) 11
risk factors (11) 11
young adult (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
expression (10) 10
medicine, general & internal (10) 10
analysis (9) 9
apoptosis (9) 9
clinical trials (9) 9
diagnosis (9) 9
disease (9) 9
disease progression (9) 9
kaplan-meier estimate (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - genetics (9) 9
multiple myeloma - mortality (9) 9
risk (9) 9
transplantation (9) 9
chemistry (8) 8
chronic myelogenous leukemia (8) 8
follow-up studies (8) 8
gene (8) 8
medicine & public health (8) 8
metallurgy (8) 8
minimal residual disease (8) 8
non-hodgkin lymphoma (8) 8
polymerase chain reaction (8) 8
research (8) 8
survival analysis (8) 8
thalidomide (8) 8
animals (7) 7
antineoplastic agents - administration & dosage (7) 7
biochemistry (7) 7
dna methylation (7) 7
drug therapy (7) 7
genetics & heredity (7) 7
lenalidomide (7) 7
microsatellite instability (7) 7
non-hodgkin's lymphomas (7) 7
thalidomide - administration & dosage (7) 7
thalidomide - analogs & derivatives (7) 7
acute myeloid-leukemia (6) 6
beer (6) 6
boronic acids - adverse effects (6) 6
cell biology (6) 6
drug resistance, neoplasm (6) 6
enzymology (6) 6
follicular lymphoma (6) 6
fusion proteins, bcr-abl - genetics (6) 6
gene rearrangement (6) 6
genetic aspects (6) 6
health risk assessment (6) 6
israel (6) 6
medical prognosis (6) 6
microbiology (6) 6
multicenter (6) 6
mutation or genetic engineering (6) 6
neutropenia (6) 6
pyrazines - adverse effects (6) 6
remission induction (6) 6
rituximab (6) 6
spirits (6) 6
stem-cell transplantation (6) 6
survival rate (6) 6
vinegar (6) 6
wine (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
cyclophosphamide (5) 5
dexamethasone - administration & dosage (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1759 - 1769
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2016, Volume 375, Issue 14, pp. 1319 - 1331
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2016, Volume 137, Issue 2, pp. AB39 - AB39
  Rationale Rituximab is a chimeric mouse-human monoclonal antibody with a paramount role in some hematological malignancies. 
Allergy and Immunology | Allergy | Allergic reaction | Hematology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
by Experts in Chronic Myeloid Leukemia, in Chronic Myeloid Leukemia and Abboud, Camille and Berman, Ellin and Cohen, Adam and Cortes, Jorge and DeAngelo, Daniel and Deininger, Michael and Devine, Steven and Druker, Brian and Fathi, Amir and Jabbour, Elias and Jagasia, Madan and Kantarjian, Hagop and Khoury, Jean and Laneuville, Pierre and Larson, Richard and Lipton, Jeffrey and Moore, Joseph O and Mughal, Tariq and O'Brien, Susan and Pinilla-Ibarz, Javier and Quintas-Cardama, Alfonso and Radich, Jerald and Reddy, Vishnu and Schiffer, Charles and Shah, Neil and Shami, Paul and Silver, Richard T and Snyder, David and Stone, Richard and Talpaz, Moshe and Tefferi, Ayalew and Van Etten, Richard A and Wetzler, Meir and Abruzzese, Elisabetta and Apperley, Jane and Breccia, Massimo and Byrne, Jenny and Cervantes, Francisco and Chelysheva, Ekaterina and Clark, R.E and De Lavallade, Hugues and Dyagil, Iryna and Gambacorti-Passerini, Carlo and Goldman, John and Haznedaroglu, Ibrahim and Hjorth-Hansen, Henrik and Holyoake, Tessa and Huntly, Brian and Le Coutre, Philipp and Lomaia, Elza and Mahon, Francois-Xavier and Marin-Costa, David and Martinelli, Giovanni and Mayer, Jiri and Milojkovic, Dragana and Olavarria, Eduardo and Porkka, Kimmo and Richter, Johan and Rousselot, Philippe and Saglio, Giuseppe and Saydam, Guray and Stentoft, Jesper and Turkina, Anna and Vigneri, Paolo and Zaritskey, Andrey and Aguayo, Alvaro and Ayala, Manuel and Bendit, Israel and Bengio, Raquel Maria and Best, Carlos and Bullorsky, Eduardo and Cervera, Eduardo and Desouza, Carmino and Fanilla, Ernesto and Gomez-Almaguer, David and Hamerschlak, Nelson and Lopez, Jose and Magarinos, Alicia and Meillon, Luis and Milone, Jorge and Moiraghi, Beatriz and Pasquini, Ricardo and Pavlovsky, Carolina and Ruiz-Arguelles, Guillermo J and Spector, Nelson and Arthur, Christopher and Browett, Peter and Grigg, Andrew and Hu, Jianda and Huang, Xiao-jun and Hughes, Tim and Jiang, Qian and Jootar, Saengsuree and Kim, Dong-Wook and Malhotra, Hemant and Malhotra, Pankaj and Matsumura, Itaru and Melo, Junia and Ohnishi, Kazunori and ... and Experts Chronic Myeloid Leukemia and Experts in Chronic Myeloid Leukemia
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 22, pp. 4439 - 4442
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2015, Volume 168, Issue 6, pp. 811 - 819
Summary Belinostat is a pan‐histone deacetylase inhibitor with antitumour and anti‐angiogenic properties. An open label, multicentre study was conducted in... 
belinostat | peripheral T cell Lymphoma | mycosis fungoides | T cell lymphoma | histone deacetylase inhibitors | Mycosis fungoides | Peripheral T cell Lymphoma | Histone deacetylase inhibitors | Belinostat | HISTONE DEACETYLASE INHIBITOR | MULTICENTER | CARBOPLATIN | RESPONSE CRITERIA | CLINICAL-TRIAL | SOLID TUMORS | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | VORINOSTAT | BEXAROTENE | HEMATOLOGY | Recurrence | Humans | Hydroxamic Acids - adverse effects | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Lymphoma, T-Cell, Cutaneous - drug therapy | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Hydroxamic Acids - administration & dosage | Adult | Female | Lymphoma, T-Cell, Peripheral - drug therapy | Drug Administration Schedule | Treatment Outcome | Lymphoma, T-Cell, Cutaneous - pathology | Sulfonamides - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Sulfonamides - adverse effects | Hydroxamic Acids - therapeutic use | Aged | Histone Deacetylase Inhibitors - therapeutic use | Infusions, Intravenous | Neoplasm Staging | Histone Deacetylase Inhibitors - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Care and treatment | Relapse | Clinical trials | Skin | Non-Hodgkin's lymphomas | Antineoplastic agents | T cells | Diseases
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2017, Volume 178, Issue 5, pp. 709 - 718
Summary This multicentre study evaluated 5‐year progression‐free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was... 
advanced‐stage Hodgkin lymphoma | interim positron emission tomography/computed tomography | early‐stage Hodgkin lymphoma | radiation therapy | Hodgkin lymphoma | early-stage Hodgkin lymphoma | advanced-stage Hodgkin lymphoma | RISK | INTERNATIONAL PROGNOSTIC SCORE | CHEMOTHERAPY | RADIATION-THERAPY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ESCALATED BEACOPP | RESPONSE-ADAPTED THERAPY | INTERPRETATION CRITERIA | HEMATOLOGY | COOPERATIVE-ONCOLOGY-GROUP | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Drug Monitoring - methods | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Bleomycin - administration & dosage | Bleomycin - adverse effects | Positron Emission Tomography Computed Tomography | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | CT imaging | Anthracyclines | Corticosteroids | PET imaging | Analysis | Lymphomas | Radiotherapy | Procarbazine | Vinblastine | Positron emission | Etoposide | Prednisone | Radiation therapy | Lymphoma | Patients | Vincristine | Dacarbazine | Cyclophosphamide | Bleomycin | Computed tomography | Medical prognosis | Tomography | Positron emission tomography | Hodgkin's disease
Journal Article